SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
Active, not recruiting · NCT05020457 · Registry updated 2025-09-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2025-09-26 | NCT05020457 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sichuan Baili Pharmaceutical Co., Ltd. | 135 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chongqing University Cancer Hospital | Chongqing | China | 33 |
| Shandong Cancer Hospital | Jinan | China | 31 |
| Sun Yat-sen University Cancer Center (SYSUCC) | Guangzhou | China | 1 |
| Taizhou Hospital of Zhejiang Province | Taizhou | China | 26 |
| The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou | China | 14 |
| The Second Affiliated Hospital of Guilin Medical University | Guilin | China | 12 |